Home » Topics » BioWorld Science

BioWorld Science
RSS

Regeneron provides updates on phase III development program of Libtayo in NSCLC

Nov. 6, 2019

Initiation of phase Ib study of mavorixafor in severe congenital neutropenia

Nov. 6, 2019

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Nov. 6, 2019

eFFECTOR Therapeutics initiates early clinical study of zotatifin in advanced solid tumors

Nov. 6, 2019

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

Nov. 6, 2019

HLX-11 receives IND application acceptance notification from NMPA

Nov. 6, 2019

Tau spreads quickly but kills slowly

Nov. 6, 2019

PARP degradation joins trapping, inhibition

Nov. 6, 2019

FDA approves influenza vaccine Fluzone High-Dose Quadrivalent

Nov. 5, 2019

Halozyme Therapeutics to halt development of PEGPH20 following phase III results

Nov. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...